Transcutaneous Electrical Nerve Stimulation for Health & Longevity

Created on 10/30/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Transcutaneous electrical nerve stimulation is a low-cost, drug-free device sending mild pulses through skin pads to quiet pain. Its clearest benefit is pain relief during use, at a strong but comfortable setting. Beyond pain, support is firmest for easing leg stiffness and walking after stroke. Whether relief lasts between sessions remains uncertain. Risks are mostly mild skin irritation, except with pacemakers, implanted defibrillators, epilepsy, or neck or chest placement. (Full Review)

Protocol

Conventional (high-frequency) TENS
80–100 Hz
Short pulses, strong but comfortable intensity near the painful area
Mixed-frequency movement protocol
2–125 Hz, about 2 hours daily
100–180 µs pulses, strong but comfortable, during activity on upper and lower back
Ear (taVNS) protocol
20 Hz, 30 minutes twice daily
Clip on the tragus, 200 µs, above perception, below discomfort
Time to effect
Pain relief
Within minutes
Greatest during stimulation; lasts mainly during and shortly after
Fibromyalgia benefit
4 weeks
With use during daily activity
Bladder benefits
6–12 weeks
Accrue over repeated ankle-stimulation sessions

Benefits

Contraindications
  • People with a cardiac pacemaker or ICD, unless tested under cardiac-device supervision
  • People with epilepsy
  • Pregnant women, except when a physician or midwife directs use, for example in labor
  • Anyone over irritated, broken, infected or numb skin at the intended site
  • Placement on the neck, mouth or eyes, or on chest and back at the same time
  • Placement over a cancerous lesion, thrombophlebitis or varicose veins, or on opposite sides of the head
  • People with marked resting bradycardia (slow heart rate), for ear stimulation: inferred; no human data on harm
Key Interactions
  • Naloxone (opioid-overdose reversal agent): A high dose blocked high-frequency TENS pain relief
  • Regular opioid analgesics (tramadol, morphine): Low-frequency TENS lost its effect; high-frequency and mixed-frequency TENS kept it
  • Caffeine (coffee, tea): Reduced TENS pain relief; one cup of coffee (100 mg caffeine) showed no interaction
Theoretical (inferred from mechanism)
  • Naltrexone, including low-dose naltrexone: Could blunt TENS pain relief
  • Heart-rate-slowing drugs (metoprolol, digoxin) with ear stimulation: Additive slowing of heart rate
  • Topical anesthetics under pads (lidocaine patches or creams): Numbed skin may hide excessive current and skin injury
  • Analgesic supplements (curcumin, omega-3 fatty acids): Additive pain relief
  • Stimulant supplements (guarana, green tea extract): Caffeine content could blunt relief
  • MRI (magnetic resonance imaging) scans and diathermy (deep-heating therapy): Induced currents could heat pads or damage the unit

Risk & Side Effects

  • High: Skin irritation and burns at electrode sites
  • Medium: Interference with pacemakers and implanted defibrillators
  • Low: Loss of effect with repeated daily use; serious events with ear stimulation; headache during or after stimulation; seizure provocation in epilepsy
  • Speculative: Blood-pressure drop, airway spasm or heart-rhythm disturbance with neck or chest placement; unknown effects in early pregnancy; harm over tumors, clotted veins or across the head

Monitoring

Marker Target Why
Pain intensity, 0–10 numeric rating scale Reduction of 30% or more from own baseline Defines response
Movement-evoked pain (0–10 during five sit-to-stand repetitions) No established target; track change from own baseline Captures activity-related relief
Skin at electrode sites No established target; track redness, blistering or itching versus prior session Safety check
Implanted cardiac device function No established target; confirm no interference during supervised test stimulation Determines whether use is possible
Resting heart rate (ear stimulation) 60–100 beats per minute Safety check; excessive slowing stops use
Heart rate variability, RMSSD (ear stimulation) No established target; track change from own baseline Marker of vagal activity
Bladder diary: incontinence, urgency and night-time voids per day (tibial stimulation) No established target; track change from own baseline Defines bladder response
Depression score, PHQ-9 (ear stimulation for low mood) No established target; track change from own baseline Tracks mood benefit

Cadence: Pain ratings during and 30 minutes after each of the first sessions; structured review at 2 weeks, 4 weeks and 3 months, then every 6 months; skin checked at every session; for ear stimulation, pulse before and after the first week of sessions, then monthly; bladder diaries and mood questionnaires at 6 and 12 weeks. Lack of meaningful change by 4 weeks suggests non-response.

Qualitative Assessment

  • Ease of walking, climbing stairs and daily tasks
  • Need for rescue pain medication, especially opioids
  • Sleep onset and quality
  • Daytime energy and fatigue during activity
  • Mood, tension and sense of calm
  • Comfort of the sensation and any skin discomfort